10th of August Zealand Pharma became the first Danish biotech company to be listed on Nasdaq in Denmark as well as the US.
With the dual listing, Zealand Pharma will become more attractive to US investors.
”To us it is an achievement and a major milestone that we today show Zealand to be an attractive player on the US biotech scene, the largest in the world. Our Nasdaq listing in New York will be a strong supplement to our primary listing on Nasdaq Copenhagen as it eases access to a large and unique group of investors in the US with highly specialized competencies,” said CEO of Zealand Pharma Britt Meelby Jensen.
”We congratulate Zealand Pharma on its listing on the Nasdaq market in New York, and hope a door to the US biotech investors has been opened. Biotech is one those sectors where American investors and analysts are highly specialized and it makes us proud to have been able to build a bridge to New York together with Zealand Pharma. We look forward to continue to support and partner with Zealand Pharma from both sides of the Atlantic,” said Adam Kostyál, SVP and Head of European listings at Nasdaq.
